title: Antiresorptive Therapies for Osteoporosis.
abstract: Osteoporosis is a disease of low bone density, translating to increased fragility and risk for fracture. It is a significant public health problem that is widely undertreated, despite the many options of treatment available. Among these, the most effective are the antiresorptive medications, such as bisphosphonates. There is an abundance of evidence about the efficacy and safety profile of these medications. However, there is mounting evidence that, after 10 years on treatment with a bisphosphonate, patients are at a higher risk of developing some of the serious side effects of atypical femur fractures and osteonecrosis of the jaw.
authors.affiliation: Division of Endocrinology & Diabetes, Department of Medicine, Hofstra North Shore-LIJ School of Medicine, 865 Northern Boulevard, Suite 203, Great Neck, New York 11021, USA. Electronic address: sweinerm@nshs.edu.
authors.forename: Stuart
authors.initials: S
authors.lastname: Weinerman
authors.affiliation: Division of Endocrinology & Diabetes, Department of Medicine, Hofstra North Shore-LIJ School of Medicine, 865 Northern Boulevard, Suite 203, Great Neck, New York 11021, USA.
authors.forename: Gianina L
authors.initials: GL
authors.lastname: Usera
mesh_terms: D059266:Bisphosphonate-Associated Osteonecrosis of the Jaw / Q000209:etiology*; D050071:Bone Density Conservation Agents / Q000009:adverse effects*; D004164:Diphosphonates / Q000009:adverse effects*; D005264:Femoral Fractures / Q000139:chemically induced*; D006801:Humans; D010024:Osteoporosis / Q000188:drug therapy*; D012307:Risk Factors
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates
keywords: Antiresorptives; Bisphosphonates; Fracture; Osteonecrosis; Osteoporosis